Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Synplogen Co., Ltd. is currently managing a patent portfolio within the Biotechnology & Pharmaceuticals technology area. The portfolio contains 1 pending office action, which represents the current focus of the company's prosecution efforts. This active matter is assigned to 1 distinct examiner, UNDERDAHL, THANE E. This indicates a highly centralized interaction between the company and the patent office, where a single individual is responsible for the initial review of the pending application.
The administrative footprint of this portfolio is limited to 1 distinct art unit. UNDERDAHL, THANE E is also identified as the busiest examiner for the company, currently handling 1 busiest examiner pending office action. Because the total number of pending office actions is 1, this examiner manages the entirety of the company's active workload in the Biotechnology & Pharmaceuticals sector. This structure ensures that all current feedback and requirements originate from a single source.
For practitioners, this data suggests a streamlined prosecution path with no fragmentation across different examiners or art units. The alignment of 1 distinct examiner with 1 distinct art unit for the 1 pending office action allows for a focused strategy. Future filings in the Biotechnology & Pharmaceuticals area may encounter similar administrative assignments, making the current relationship with UNDERDAHL, THANE E a significant factor in the company's patenting process.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MARVICH, MARIA | 1 | 55.0% | +28.0% |
| UNDERDAHL, THANE E | 1 | 58.8% | +50.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19042220 | PRODUCTION OF VIRUS VECTOR PLASMID IN BACILLUS SUBTILIS | MARVICH, MARIA | 55d |
| 18251792 | INTEGRATIVE PLASMID | UNDERDAHL, THANE E | — |
| Art Unit | Apps |
|---|---|
| 1634 | 1 |
| 1699 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19042220 | PRODUCTION OF VIRUS VECTOR PLASMID IN BACILLUS SUBTILIS | MARVICH, MARIA | 1634 | §112Other | Final Rejection | 55d | Pending | Jan 31, 2025 |
| 18251792 | INTEGRATIVE PLASMID | UNDERDAHL, THANE E | 1699 | §103§112DP | Non-Final OA | — | Pending | May 04, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSynplogen Co., Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Maria Marvich has the most, with 1 of Synplogen Co., Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
